ReviewCurrent diabetes reports2012
Neuropathic pain: is quantitative sensory testing helpful?
Review in Current diabetes reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- Neuropathic pain in burn patients - A common problem with little literature: A systematic review.Burns : journal of the International Society for Burn Injuries · 2024Pooled it
- Trial
- NerveCheck: An inexpensive quantitative sensory testing device for patients with diabetic neuropathy.Diabetes research and clinical practice · 2016Trial
- Trial
- Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy.Cancer chemotherapy and pharmacology · 2013Trial
- Amygdalar calcitonin gene-related peptide driven effects of cold sensitivity induced by peripheral neuropathy in mice.The journal of pain · 2026Article
- New insight into RNA biomarkers in neuropathic pain: a clinician-neuroscientist roadmap to translational testing and treatment monitoring a clinical review.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Clinical Phenotypes of Diabetic Peripheral Neuropathy: Implications for Phenotypic-Based Therapeutics Strategies.Diabetes & metabolism journal · 2025Review
- Quantitative sensory testing for pain: What exactly are we measuring?Current opinion in psychology · 2025Review
- Classifying Low Back Pain Through Pain Mechanisms: A Scoping Review for Physiotherapy Practice.Journal of clinical medicine · 2025Review
- Review
- Pathology of pain and its implications for therapeutic interventions.Signal transduction and targeted therapy · 2024Review
- Article
- Guidelines for chronic pain in adult spinal cord injury population: Scoping review.The South African journal of physiotherapy · 2024Article
- Psychophysics of Pain: A Methodological Introduction.Pain management nursing : official journal of the American Society of Pain Management Nurses · 2023Article
- Quantitative sensory testing in a magnetic resonance environment: considerations for thermal sensitivity and patient safety.Frontiers in pain research (Lausanne, Switzerland) · 2023Article
- [Quantitative sensory testing for neuropathic pain and its relevance for physiotherapy].Schmerz (Berlin, Germany) · 2022Review
- Diabetic corneal neuropathy as a surrogate marker for diabetic peripheral neuropathy.Neural regeneration research · 2022Review
- The Value of In Vivo Reflectance Confocal Microscopy as an Assessment Tool in Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study.The oncologist · 2022Article
- Network-Based Methods for Approaching Human Pathologies from a Phenotypic Point of View.Genes · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic pain arises as a consequence of a lesion or disease affecting the somatosensory system and is characterised by a combination of positive and negative sensory symptoms. Quantitative sensory testing (QST) examines the sensory perception after application of different mechanical and thermal stimuli of controlled intensity and the function of both large (A-beta) and small (A-delta and C) nerve fibres, including the corresponding central pathways. QST can be used to determine detection, pain thresholds and stimulus-response curves and can thus detect both negative and positive sensory signs, the second ones not being assessed by other methods. Similarly to all other psychophysical tests QST requires standardised examination, instructions and data evaluation to receive valid and reliable results. Since normative data are available, QST can contribute also to the individual diagnosis of neuropathy, especially in the case of isolated small-fibre neuropathy, in contrast to the conventional electrophysiology which assesses only large myelinated fibres. For example, detection of early stages of subclinical neuropathy in symptomatic or asymptomatic patients with diabetes mellitus can be helpful to optimise treatment and identify diabetic foot at risk of ulceration. QST assessed the individual's sensory profile and thus can be valuable to evaluate the underlying pain mechanisms which occur in different frequencies even in the same neuropathic pain syndromes. Furthermore, assessing the exact sensory phenotype by QST might be useful in the future to identify responders to certain treatments in accordance to the underlying pain mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.